We read with interest the paper Idiopatic Intracranial Hypertension without papilledema in Chronic Headache by Favoni et al. ([@B1]) and wish to congratulate with the Authors. Actually, their data independently confirm our original main findings ([@B2]) that a raised intracranial pressure may be causatively involved the progression of migraine pain and that a single lumbar puncture (LP) with cerebrospinal fluid withdrawal may provide a long term benefit in many such patients. Moreover, their observations also substantiate our criticism to the revised IIH/IIHWOP diagnostic criteria by Friedman ([@B3]), demonstrating their unacceptably low sensitivity.

In their series of retrospectively assessed refractory CM patients they have found a 22.5% prevalence of cases with opening pressure \> 200, most of which (77.8%) showed a prompt and sustained remission of chronic pain after LP. This finding is higher than IIHWOP prevalence reported in non-selected series of CM, ranging between 10 and 14% ([@B4], [@B5]). However, as the authors highlight, it is significantly lower than the prevalence reported in our original study (86.4%) ([@B2]). This discrepancy may relay on differences in patients selection leading to quite different populations. Actually, almost all their patients (92.5%) presented a medication overuse headache (MOH), a known risk factor for pain progression, while in our sample MOH prevalence was 59.1%. Moreover, in our screened population of 56 subjects with documented unresponsiveness to preventative treatments we found a prevalence of "bilateral transverse sinus (TS) stenosis/hypoplasia or at least unilateral segmental TS flow gap/aplasia at uncontrasted MRV" of 92.8%. Unfortunately, in the Favoni et al. work this data is not specified. However, in a previous very similar version of the paper by Favoni et al. ([@B6]) the overall sinus stenosis prevalence was only 48%.

Last, neither in the first nor in the actual version of the Favoni et al. works it is clear weather refractoriness was assessed prospectively or retrospectively. Our study was conducted on a series of CM patients with a prospectively assessed refractoriness to medical treatments, after the failure of 2 subsequent pharmacological treatments of at least 2 month each (median 12.2 weeks; range 8.3--23.8), with appropriate drugs (included in a list of 7) at adequate dosages. This procedure allowed us to select only 56 out of 278 patient (20.1%) consecutively diagnosed with CM at our tertiary headache center. Again, in both versions of the Favoni et al. works ([@B1], [@B6]) the size of the original screened population of CM patients is not provided.

The assessment of refractoriness is a crucial issue in headache research. CM patient referring to a tertiary headache center for the first time very often complain of a long history of disease and usually report a number of previous failed treatments and/or medication overuse withdrawal. However, this is not enough to classify them as true refractory since retrospective assessment of CM refractoriness is unrelialable ([@B7]).
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